Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study
- 149 Downloads
Despite median survival of less than 6 months, there is a significant proportion of advanced pancreatic cancer patients who progress on gemcitabine that remains fit, and these patients are candidates for second-line treatment.
The objective of this study is to evaluate the efficacy and safety of oxaliplatin plus 5-fluorouracil and folinic acid in patients with gemcitabine-pretreated advanced pancreatic cancer.
Patients and Methods
Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m2) on days 1 and 15 followed by leucovorin (20 mg/m2) and 5-fluorouracil (500 mg/m2) on days 1, 8, and 15. The cycle was repeated every 3 weeks.
The majority of patients (80 %) had locally advanced disease. Median age was 63 years, and 60 % were males. The liver was the most common site of metastasis. Partial response was observed in 2 patients (6.7 %) and stable disease in 6 patients (20 %), while 12 patients progressed (40 %). Improved performance status was reported in 10 patients (33.3 %). The median duration of response was 13 weeks, and median overall survival was 22 weeks. There was no grade 4 toxicity apart from grade 4 neutropenia in 6.6 % of patients. Neutropenia (46.5 %) and neuropathy (43.2 %) were the most common toxicities, while hand–foot syndrome was the least frequent one (20 %). There were no treatment-related deaths. The 6-month survival rate was 30 %.
This regimen is feasible and active with an acceptable toxicity; however, further investigation in phase III trial is needed.
KeywordsOxaliplatin Locally advanced pancreatic cancer Pretreated pancreatic cancer Oxaliplatin plus 5-fluorouracil and folinic acid
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets. 2009. http://seer.cancer.gov/csr/1975_2009_pops09, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
- 6.Guarneri D, Venturino A, Addamo G. Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: preliminary results. Ann Oncol. 2002;13 Suppl 5:87.Google Scholar
- 12.Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin or CPT-11 +5FU/LV or oxaliplatin + CPT-11 in advanced colorectal cancer. Paper presented at the 39th annual meeting of the American Society of Clinical Oncology, Chicago; 2003. 31 May–3 June 2003.Google Scholar
- 14.Schrag D, Archer L, Wang X, et al. A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25(Suppl pt 1):4524.Google Scholar
- 18.Van Laethem JL, Polus M, Marechal R, et al. Gemcitabine and oxaliplatin in gemcitabine-refractory advanced pancreatic cancer: a phase II study. Proc Am Soc Clin Oncol. 2004;23:4119.Google Scholar
- 24.Mysliviec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients—rationale for new therapy. Adv Med Sci. 2009;54:136–42.Google Scholar